Clover

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:1000 publications

Grant number: N/A

Grant search

Key facts

  • Disease

    COVID-19
  • Known Financial Commitments (USD)

    $328,000,000
  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)
  • Principal Investigator

    N/A

  • Research Location

    China
  • Lead Research Institution

    Clover Biopharma
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Protein: Native-like Trimeric Subunit Vaccine Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Last Updated:2 hours ago

View all publications at Europe PMC

Impact of postpartum physical activity on maternal anthropometrics: a systematic review and meta-analysis.

Redox dye-mediated fluorescence energy transfer of carbon nanotube-based nanosensors.

Disease burden by <i>ALPL</i> variant number in patients with non-life-threatening hypophosphatasia in the Global HPP Registry.

Comprehensive mutant chemotyping reveals embedding of a lineage-specific biosynthetic gene cluster in wider plant metabolism.

lncreased risk of slippage upon disengagement of the mitotic checkpoint.

Exploring caregiver support: healthcare leaders' perspectives on medical errors.

Health measurement instruments and their applicability to military veterans: a systematic review.

Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells.